CHUGAI PHARMACEUTICAL CO., LTD.
- Country
- π―π΅Japan
- Ownership
- Public, Subsidiary
- Established
- 1925-03-10
- Employees
- 7.6K
- Market Cap
- $83.6B
A Study of ERY974 in Patient With Advanced Solid Tumors
- First Posted Date
- 2016-04-22
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 29
- Registration Number
- NCT02748837
A Single Ascending Dose Study of PCO371 in Healthy Volunteers
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 64
- Registration Number
- NCT02475616
- Locations
- πΊπΈ
Wcct Global, Cypress, California, United States
Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30
- Conditions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 43
- Registration Number
- NCT02431117
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 264
- Registration Number
- NCT01986933
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT01656525
- Locations
- π―π΅
Kansai region, Kansai, Japan
π―π΅Kanto region,, Kanto, Japan
π―π΅Kyushu region, Kyushu, Japan
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
- First Posted Date
- 2009-09-14
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 42
- Registration Number
- NCT00976170
- Locations
- πΊπΈ
California Pacific Medical Center, San Francisco, California, United States
π¨π³National Taiwan Univercity Hospital, Taipei, Taiwan
πΊπΈUniversity of Miami, Miami, Florida, United States
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 152
- Registration Number
- NCT00779220
- Locations
- π―π΅
Chugoku region, Chugoku, Japan
π―π΅Sikoku region, Sikoku, Japan
π―π΅Chubu region, Chubu, Japan
A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 27
- Registration Number
- NCT00746317
- Locations
- πΊπΈ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈKarmanos Cancer Center at the Detroit Medical Center, Detroit, Michigan, United States
πΊπΈUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)
- Conditions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 189
- Registration Number
- NCT00661284
- Locations
- π―π΅
Kanto region, Kanto, Japan
π―π΅Kyushu region, Kyushu, Japan
π―π΅Chugoku region, Chugoku, Japan
Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Chugai Pharmaceutical
- Target Recruit Count
- 160
- Registration Number
- NCT00628043
- Locations
- π―π΅
Chugoku/Shikoku Region, Chugoku/Shikoku, Japan
π―π΅Chubu Region, Chubu, Japan
π―π΅Kyushu Region, Kyushu, Japan